Disease · HP_0001636
Tetralogy of Fallot
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Tetralogy of Fallot. Diseases, record HP_0001636. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001636
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DEXMEDETOMIDINE | CHEMBL778 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LOSARTAN | CHEMBL191 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NITRIC OXIDE | CHEMBL1200689 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROPRANOLOL | CHEMBL27 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALPHA-TOCOPHEROL | CHEMBL47 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HISTIDINE | CHEMBL17962 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| TRYPTOPHAN | CHEMBL54976 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NESIRITIDE | CHEMBL1201668 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
Targets11
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2/3 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2/3 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2/3 | https://conductscience.org/library/genes/152 | Drugs and targets |
| ADRB1 | Beta-1 adrenergic receptor | 1 | Beta-1 adrenergic receptor antagonist | Phase 1 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Beta-2 adrenergic receptor | 1 | Beta-2 adrenergic receptor antagonist | Phase 1 | https://conductscience.org/library/genes/154 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 1 | Type-1 angiotensin II receptor antagonist | Phase 2 | https://conductscience.org/library/genes/185 | Drugs and targets |
| GUCY1A1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 1/2 | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 1/2 | https://conductscience.org/library/genes/2977 | Drugs and targets |
| GUCY1B1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 1/2 | https://conductscience.org/library/genes/2983 | Drugs and targets |
| NPR1 | Atrial natriuretic peptide receptor 1 | 1 | Atrial natriuretic peptide receptor A agonist | Unknown | https://conductscience.org/library/genes/4881 | Drugs and targets |
1 to 10 of 11
See all 11 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00585013 | Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass | Phase 1/2 | 17 | 2015-11-04 | Congenital Heart Disease | NITRIC OXIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02010905 | Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System | Phase 2 | 120 | Tetralogy of Fallot, Heart Defects, Congenital, Ventricular Dysfunction, Right | LOSARTAN | Its record names the disease | ClinicalTrials.gov | |
| NCT05579964 | The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot | Phase 2/3 | 66 | Congenital Heart Disease in Children, Cardiopulmonary Bypass, Tetralogy of Fallot | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07194304 | Effect of Parenteral Alpha-Tocopherol in the Definitive Surgery of Tetralogy of Fallot | Early phase 1 | 60 | Tetralogy of Fallot (TOF), Alpha-tocopherol, Cardiac Surgery | ALPHA-TOCOPHEROL | Its record names the disease | ClinicalTrials.gov | |
| NCT04713657 | Beta-blocker Administration for Cardiomyocyte Division | Phase 1 | 40 | Tetralogy of Fallot, Double Outlet Right Ventricle | PROPRANOLOL | Its record names the disease | ClinicalTrials.gov | |
| NCT05691764 | Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery | Not applicable | 40 | Myocardial Injury, Cardiac Surgery | CYCLOSPORINE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| 1 Treatment vs 2 Placebo: serious adverse events | 0 of 8 | 0 of 8 | 16 | NCT00585013 |
Source Trial comparisons
Papers from its trials7
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001636
GET https://conductscience.org/api/diseases/v1/HP_0001636/drugs